• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck,...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 02, 2024 at 11:42: AM
via Ipsen has become the newest entrant in the antibody-drug conjugate (ADC) race, handing over around $90 million in near-term payments to Sutro Biopharma in return for the global rights to a preclinical candidate.

article source
 




Top Bottom
Back
Quote